NEVADA CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

Not Applicable

Conditions: Early Stage Breast Cancer (Stage 0-III)

Interventions: Other: Exercise Regimen

First Posted Date: 2010-07-05

Last Posted Date: 2011-07-20

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 100

Registration Number: NCT01157130

Locations: 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Phase 2

Withdrawn

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: ofatumumab + bendamustine

First Posted Date: 2010-05-26

Last Posted Date: 2011-07-20

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 37

Registration Number: NCT01131247

Locations: 🇺🇸
Mayo Clinic, PHoenix/Scottsdale, Arizona, United States

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: ofatumumab + bendamustine

First Posted Date: 2010-05-18

Last Posted Date: 2011-07-20

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01125787

Locations: 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: Decitabine and Pegylated Interferon-Alfa 2B

First Posted Date: 2009-04-23

Last Posted Date: 2011-07-20

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00886457

Locations: 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

Phase 1

Terminated

Conditions: B Cell Lymphoma
T Cell Lymphoma

Interventions: Drug: Poly-ICLC

First Posted Date: 2009-04-14

Last Posted Date: 2011-07-20

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00880867

Locations: 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer and Pleural Mesothelioma

First Posted Date: 2006-01-24

Last Posted Date: 2012-03-19

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00281125

Locations: 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy